Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Raw Materials (2023 - 2025)

Krystal Biotech (KRYS) has disclosed Raw Materials for 3 consecutive years, with $15.9 million as the latest value for Q4 2025.

  • Quarterly Raw Materials rose 16.86% to $15.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.9 million through Dec 2025, up 16.86% year-over-year, with the annual reading at $15.9 million for FY2025, 16.86% up from the prior year.
  • Raw Materials hit $15.9 million in Q4 2025 for Krystal Biotech, up from $14.6 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $15.9 million in Q4 2025 to a low of $3.2 million in Q4 2023.
  • Historically, Raw Materials has averaged $10.6 million across 3 years, with a median of $13.6 million in 2024.
  • Biggest five-year swings in Raw Materials: soared 332.44% in 2024 and later grew 16.86% in 2025.
  • Year by year, Raw Materials stood at $3.2 million in 2023, then skyrocketed by 332.44% to $13.6 million in 2024, then increased by 16.86% to $15.9 million in 2025.
  • Business Quant data shows Raw Materials for KRYS at $15.9 million in Q4 2025, $14.6 million in Q3 2025, and $14.1 million in Q2 2025.